We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NSTG
101
DELISTED
NanoString Technologies, Inc.
NSTG
-280,695
Closed -$9.75M
ORTX
102
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
-41,958
Closed -$299K
SYNH
103
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
-81,416
Closed -$6.59M
CLVS
104
DELISTED
Clovis Oncology, Inc.
CLVS
-30,000
Closed -$60.6K
OCDX
105
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
-445,059
Closed -$8.3M
SRGA
106
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
-52,460
Closed -$479K

Similar funds

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.